Page last updated: 2024-11-05

thalidomide and Parasystole

thalidomide has been researched along with Parasystole in 1 studies

Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.

Parasystole: A cardiac arrhythmia that is caused by interaction of two independently initiated cardiac impulses of different rates from two separate foci. Generally one focus is the SINOATRIAL NODE, the normal pacemaker. The ectopic focus is usually in the HEART VENTRICLE but can be in the HEART ATRIUM or the ATRIOVENTRICULAR NODE. Modulation of the parasystolic rhythm by the sinus rhythm depends on the completeness of entrance block surrounding the parasystolic focus.

Research Excerpts

ExcerptRelevanceReference
"Thalidomide was therefore suggested as atherapeutic intervention for the treatment of ALS."6.73Thalidomide causes sinus bradycardia in ALS. ( Borisow, N; Dullinger, JS; Linke, P; Maier, A; Meyer, T; Münch, C; Ohlraun, S; Splettstösser, G, 2008)
"Thalidomide was therefore suggested as atherapeutic intervention for the treatment of ALS."2.73Thalidomide causes sinus bradycardia in ALS. ( Borisow, N; Dullinger, JS; Linke, P; Maier, A; Meyer, T; Münch, C; Ohlraun, S; Splettstösser, G, 2008)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Meyer, T1
Maier, A1
Borisow, N1
Dullinger, JS1
Splettstösser, G1
Ohlraun, S1
Münch, C1
Linke, P1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Randomized, Open, Parallel Group Study for the Evaluation of an Oral Dose of 100 mg Thalidomide and Subsequent Dose Escalation of 400 mg Thalidomide in Combination With Riluzole in Patients With Amyotrophic Lateral Sclerosis (ALS)[NCT00231140]Phase 240 participants Interventional2005-12-31Terminated
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trials

1 trial available for thalidomide and Parasystole

ArticleYear
Thalidomide causes sinus bradycardia in ALS.
    Journal of neurology, 2008, Volume: 255, Issue:4

    Topics: Adult; Aged; Amyotrophic Lateral Sclerosis; Anti-Inflammatory Agents; Arrhythmia, Sinus; Bradycardia

2008